Autopsy report · NCT03933397
Comparing Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease
Cause of deathStaffing, sites or logistics
“Due to COVID enrollment numbers needed to meet the primary endpoint will not be met.”
Life of this trial
- Registered 3 months before it started.
- Ran for about 2 years 9 months before it stopped.
- 328 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Conditions
- Sickle Cell Disease
- Interventions
- Patient-Specific Protocol; Weight-based Protocol; Morphine; Hydromorphone
- Participants
- 328
- Sites
- 6
- Countries
- United States
Trials that died the same way
- Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption
“Due to limitations caused by COVID, enrollment targets could not be met.” - Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
“IA did not meet the prespecified primary endpoint.” - A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)
“The primary endpoint at 15 months was not met.” - A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
“The study did not meet the primary endpoint.” - CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
“Primary Endpoint not met”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.